0001193125-20-169361.txt : 20200615 0001193125-20-169361.hdr.sgml : 20200615 20200615161619 ACCESSION NUMBER: 0001193125-20-169361 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200609 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200615 DATE AS OF CHANGE: 20200615 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMEDISYS INC CENTRAL INDEX KEY: 0000896262 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 113131700 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-24260 FILM NUMBER: 20963460 BUSINESS ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 BUSINESS PHONE: 2252922031 MAIL ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 FORMER COMPANY: FORMER CONFORMED NAME: ANALYTICAL NURSING MANAGEMENT CORP DATE OF NAME CHANGE: 19940819 FORMER COMPANY: FORMER CONFORMED NAME: M&N CAPITAL CORP DATE OF NAME CHANGE: 19930125 8-K 1 d944425d8k.htm 8-K 8-K
AMEDISYS INC false 0000896262 0000896262 2020-06-09 2020-06-09

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 9, 2020

Commission File Number: 0-24260

 

IMAGE

Amedisys, Inc.

(Exact name of registrant as specified in charter)

 

Delaware

  

11-3131700

(State or other jurisdiction of

incorporation or organization)

  

(IRS Employer

Identification No.)

3854 American Way, Suite A, Baton Rouge, LA 70816

(Address of principal executive offices, including zip code)

(225) 292-2031 or (800) 467-2662

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.001 per share

  

AMED

  

The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

Section 1 – Registrant’s Business and Operations

Item 1.01 Entry into a Material Definitive Agreement.

On June 12, 2020, in connection with the previously announced acquisition by Amedisys, Inc. (the “Company”) of HomeCare Preferred Choice, Inc. and its subsidiaries, doing business as AseraCare Hospice (collectively, the “Acquired Companies”), the Company, Amedisys Holding, L.L.C. (“Holding” and together with the Company, the “Borrowers”) and the Acquired Companies entered into a Joinder Agreement (the “Joinder”), dated as of June 12, 2020, by and among the Borrowers, the Acquired Companies and Bank of America, N.A. (the “Administrative Agent”), in its capacity as administrative agent under that certain Amended and Restated Credit Agreement, dated as of June 29, 2018 (as amended to date, the “Credit Agreement”). By virtue of the Joinder, the Acquired Companies were made parties to, and became subject to the terms and conditions of, the Credit Agreement, the Amended and Restated Security Agreement, dated as of June 29, 2018, by and among the Borrowers, the grantors party thereto and the Administrative Agent (the “Amended and Restated Security Agreement”), and the Amended and Restated Pledge Agreement, dated as of June 29, 2018, by and among the Borrowers, the pledgors party thereto and the Administrative Agent (the “Amended and Restated Pledge Agreement”).

Pursuant to the Joinder, the Amended and Restated Security Agreement, and the Amended and Restated Pledge Agreement, the Acquired Companies granted in favor of the Administrative Agent a first lien security interest in substantially all of their personal property assets and pledged to the Administrative Agent each of their respective subsidiaries’ issued and outstanding equity interests. The Acquired Companies also guaranteed the Borrowers’ obligations, whether now existing or arising after the effective date of the Joinder, under the Credit Agreement pursuant to the terms of the Joinder and the Credit Agreement.

A copy of the Joinder is attached to this Current Report on Form 8-K as Exhibit 10.1 and is incorporated herein by reference. The foregoing description of the Joinder does not purport to be complete and is qualified in its entirety by reference to Exhibit 10.1 to this Current Report on Form 8-K.

Section 2 – Financial Information

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

On June 12, 2020, the Company entered into the Joinder, as further described under Item 1.01 of this Current Report on Form 8-K, which disclosures are incorporated herein by reference.

Section 5 – Corporate Governance and Management

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Company held its annual meeting of stockholders on Tuesday, June 9, 2020 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on three proposals. A brief description of and tabulation of votes for each proposal are set forth below.

Proposal 1. The Company’s stockholders elected the following eight directors for a term of one year. There were 1,127,781 broker non-votes with respect to the proposal.

Nominee

 

For

   

Withheld

 

Vickie L. Capps

   

28,987,443

     

174,866

 

Molly J. Coye, MD

   

28,992,510

     

169,799

 

Julie D. Klapstein

   

28,736,341

     

425,968

 

Teresa L. Kline

   

28,988,187

     

174,122

 

Paul B. Kusserow

   

28,027,610

     

1,134,699

 

Richard A. Lechleiter

   

28,563,099

     

599,210

 

Bruce D. Perkins

   

28,759,705

     

402,604

 

Jeffrey A. Rideout, MD

   

28,753,947

     

408,362

 

Proposal 2. The Company’s stockholders ratified the selection of KPMG LLP as the Company’s independent registered public accountants for the fiscal year ending December 31, 2020. There were no broker non-votes with respect to the proposal.

For

 

Against

 

Abstain

29,632,422

 

635,294

 

22,374

Proposal 3. The Company’s stockholders approved, on an advisory (non-binding) basis, the compensation paid to the Company’s named executive officers. There were 1,127,781 broker non-votes with respect to the proposal.

For

 

Against

 

Abstain

27,971,063

 

1,160,987

 

30,259

SECTION 9 - FINANCIAL STATEMENTS AND EXHIBITS

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number

   

Description

         
 

10.1

   

Joinder Agreement, dated as of June 12, 2020, by and among Amedisys, Inc. and Amedisys Holding, L.L.C., as the borrowers, each of the new subsidiary guarantors party thereto, and Bank of America, N.A., as the administrative agent (The schedules to the Joinder have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company will furnish copies of the omitted schedules to the Securities and Exchange Commission upon request.)

         
 

104

   

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMEDISYS, INC.

     

By:

 

/s/ Paul B. Kusserow

 

Paul B. Kusserow

 

President, Chief Executive Officer and Chairman of the Board

 

DATE: June 15, 2020

EX-10.1 2 d944425dex101.htm EX-10.1 EX-10.1

Exhibit 10.1

Execution Version

Joinder Agreement

THIS JOINDER AGREEMENT (this “Agreement”), dated as of June 12, 2020, is by and among Hospice Preferred Choice, Inc., a Delaware corporation (“Hospice Preferred”), Hospice of Eastern Carolina, Inc., a North Carolina corporation (“Hospice Eastern Carolina”), HomeCare Preferred Choice, Inc., a Delaware corporation (“HomeCare Preferred”), AseraCare Hospice – Tennessee, LLC, a Delaware limited liability company (“ACH Tennessee”), AseraCare Hospice – Senatobia, LLC, a Delaware limited liability company (“ACH Senatobia”), AseraCare Hospice – Russellville, LLC, a Delaware limited liability company (“ACH Russellville”), AseraCare Hospice – New Horizons, LLC, a Delaware limited liability company (“ACH New Horizons”), AseraCare Hospice – Monroeville, LLC, a Delaware limited liability company(“ACH Monroeville”), AseraCare Hospice – Jackson, LLC, a Delaware limited liability company (“ACH Jackson”), AseraCare Hospice – Hamilton, LLC, a Delaware limited liability company (“ACH Hamilton”), AseraCare Hospice – Demopolis, LLC, a Delaware limited liability company (“ACH Demopolis”) and, together with Hospice Preferred, Hospice Eastern Carolina, Homecare Preferred, ACH Tennessee, ACH Senatobia, ACH Russellville, ACH New Horizons, ACH Monroeville, ACH Jackson, and ACH Hamilton, each a “Subsidiary Guarantor” and, collectively, the “Subsidiary Guarantors”), Amedisys, Inc., a Delaware corporation (the “Company”), Amedisys Holding, L.L.C., a Louisiana limited liability company (“Amedisys Holding” and together with the Company, each a “Borrower” and collectively, the “Borrowers”), and Bank of America, N.A., in its capacity as administrative agent (in such capacity, the “Administrative Agent”), under that certain Amended and Restated Credit Agreement, dated as of June 29, 2018 (as amended, modified, extended, restated, replaced, or supplemented from time to time, the “Credit Agreement”), by and among the Borrowers, the Guarantors party thereto, the Lenders from time to time party thereto and Bank of America, N.A., as Administrative Agent, Swingline Lender and L/C Issuer. Capitalized terms used herein but not otherwise defined shall have the meanings provided in the Credit Agreement.

The Loan Parties are required by Section 6.13 of the Credit Agreement to cause each Subsidiary Guarantor to become a “Guarantor” thereunder.

Accordingly, each Subsidiary Guarantor and the Borrowers hereby agree as follows with the Administrative Agent, for the benefit of the Secured Parties:

1.    Each Subsidiary Guarantor hereby acknowledges, agrees and confirms that, by its execution of this Agreement, such Subsidiary Guarantor will be deemed to be a party to and a “Guarantor” under the Credit Agreement and shall have all of the rights and obligations of a Guarantor thereunder as if it had executed the Credit Agreement and the other Loan Documents as a Guarantor. Each Subsidiary Guarantor hereby ratifies, as of the date hereof, and agrees to be bound by, all representations and warranties, covenants and other terms, conditions and provisions of the Credit Agreement and the other applicable Loan Documents. Without limiting the generality of the foregoing terms of this Paragraph 1, each Subsidiary Guarantor hereby guarantees, jointly and severally together with the other Guarantors, the prompt payment of the Secured Obligations in accordance with Article X of the Credit Agreement.

2.    Each of the Subsidiary Guarantors and the Borrowers hereby agree that all of the representations and warranties contained in Article II and Article V of the Credit Agreement or any other Loan Document, or which are contained in any document furnished at any time under or in connection herewith or therewith, are true and correct in all material respects (and in all respects if any such representation or warranty is already qualified by materiality or reference to Material Adverse Effect) on and as of the date hereof, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they shall be true and correct in all material respects (and in all respects if any such representation or warranty is already qualified by materiality or reference to Material Adverse Effect) as of such earlier date, and except for the purposes of this Agreement, the representations and warranties

 

1

contained in subsections (a) and (b) of Section 5.05 of the Credit Agreement shall be deemed to refer to the most recent statements furnished pursuant to clauses (a) and (b), respectively, of Section 6.01 of the Credit Agreement.

3.    Each Subsidiary Guarantor hereby acknowledges, agrees and confirms that, by its execution of this Agreement, such Subsidiary Guarantor will be deemed to be a party to the Security Agreement, and shall have all the obligations of a “Grantor” (as such term is defined in the Security Agreement) thereunder as if it had executed the Security Agreement. Each Subsidiary Guarantor hereby ratifies, as of the date hereof, and agrees to be bound by, all of the terms, provisions and conditions contained in the Security Agreement. Without limiting the generality of the foregoing terms of this Paragraph 3, each Subsidiary Guarantor hereby grants to the Administrative Agent, for the benefit of the Secured Parties, a continuing security interest in, and a right of set off against any and all right, title and interest of such Subsidiary Guarantor in and to the Collateral (as such term is defined in Section 2 of the Security Agreement) of such Subsidiary Guarantor.

4.    Each Subsidiary Guarantor hereby acknowledges, agrees and confirms that, by its execution of this Agreement, such Subsidiary Guarantor will be deemed to be a party to the Pledge Agreement, and shall have all the rights and obligations of a “Pledgor” (as such term is defined in the Pledge Agreement) thereunder as if it had executed the Pledge Agreement. Each Subsidiary Guarantor hereby ratifies, as of the date hereof, and agrees to be bound by, all of the terms, provisions and conditions contained in the Pledge Agreement. Without limiting the generality of the foregoing terms of this Paragraph 4, each Subsidiary Guarantor hereby grants to the Administrative Agent, for the benefit of the Secured Parties, a continuing security interest in, and a right of set off against any and all right, title and interest of such Subsidiary Guarantor in and to the Pledged Collateral (as such term is defined in Section 2 of the Pledge Agreement) of such Subsidiary Guarantor.

5.    Each Subsidiary Guarantor acknowledges and confirms that it has received a copy of the Credit Agreement and the schedules and exhibits thereto and each other Loan Document and the schedules and exhibits thereto. Each Subsidiary Guarantor hereby represents and warrants to the Administrative Agent, for the benefit of the Secured Parties, that:

(a)    Set forth on Schedule 1 attached hereto are the Responsible Officers of each Subsidiary Guarantor, holding the offices indicated next to their respective names, as of the date hereof, and such Responsible Officers are the duly elected and qualified officers of each Subsidiary Guarantor and are duly authorized to execute and deliver, on behalf of each Subsidiary Guarantor, this Agreement, and the other Loan Documents.

(b)    Set forth on Schedule 2 attached hereto is complete and accurate list as of the date hereof of (i) all Subsidiaries, joint ventures and partnerships and other equity investments of each Subsidiary Guarantor, (ii) the number of shares of each class of Equity Interests in each Subsidiary Guarantor outstanding, (iii) the number and percentage of outstanding shares of each class of Equity Interests owned by each Subsidiary Guarantor and its Subsidiaries, (iv) the class or nature of such Equity Interests (i.e. voting, non-voting, preferred, etc.), and (v) identification of each Subsidiary that is an Excluded Subsidiary. The outstanding Equity Interests in all Subsidiaries of each Subsidiary Guarantor are validly issued, fully paid and non-assessable (other than, with respect to non-Wholly Owned Subsidiaries, customary capital contribution requirements) and are owned free and clear of all Liens.

(c)    Set forth on Schedule 3 attached hereto is a complete and accurate list as of the date hereof of each Subsidiary Guarantor’s (i) exact legal name, (ii) former legal names in the four (4) months prior to the date hereof, if any, (iii) jurisdiction of its incorporation or organization, as

 

2

applicable, (iv) type of organization, (v) chief executive office address (and, if different, principal place of business address), (vi) U.S. federal taxpayer identification number, and (vii) organization identification number.

(d)    Set forth on Schedule 4 attached hereto is a list of all Intellectual Property registered or pending registration with the United States Copyright Office or the United States Patent and Trademark Office and owned by any Subsidiary Guarantor as of the date hereof. Except for such claims and infringements that could not reasonably be expected to have a Material Adverse Effect, no claim has been asserted and is pending by any Person challenging or questioning the use of such Intellectual Property or the validity or effectiveness of such Intellectual Property, nor does any Subsidiary Guarantor know of any such claim, and, to the knowledge of each Subsidiary Guarantor, the use of such Intellectual Property by such Subsidiary Guarantor or any of its Subsidiaries or the granting of a right or a license in respect of such Intellectual Property from such Subsidiary Guarantor or any of its Subsidiaries does not infringe on the rights of any Person. As of the date hereof, none of the Intellectual Property owned by any Subsidiary Guarantor or any of their Subsidiaries is subject to any licensing agreement or similar arrangement except as set forth on Schedule 4 attached hereto.

(e)    Set forth on Schedule 5 attached hereto is a description of all deposit accounts and securities accounts of each Subsidiary Guarantor as of the date hereof, including (i) in the case of a deposit account, the depository institution and average amount held in such deposit account and whether such account is an Excluded Deposit and Securities Account, and (ii) in the case of a securities account, the securities intermediary or issuer and the average aggregate market value held in such securities account and whether such account is an Excluded Deposit and Securities Account.

(f)    Set forth on Schedule 6 attached hereto is a list of all real property located in the United States that is owned or leased by each Subsidiary Guarantor as of the date hereof (in each case, including (i) if such real property is a Mortgaged Property, the number of buildings located on such property, (ii) the property address, and (iii) the city, county (if such real property is a Mortgaged Property), state and zip code which such property is located).

(g)    Set forth on Schedule 7 attached hereto is a list of all Commercial Tort claims of any Subsidiary Guarantor seeking damages in excess of $100,000.

(h)    Set forth on Schedule 8 attached hereto is a description of all Instruments, Documents or Tangible Chattel Paper required to be pledged and delivered to the Administrative Agent pursuant to Section 4(a) of the Security Agreement held by any Subsidiary Guarantor.

6.    The address and contact information of each Subsidiary Guarantor for purposes of all notices and other communications is 209 10th Avenue South, Suite 512, Nashville, TN 37203.

7.    Each Subsidiary Guarantor hereby waives acceptance by the Administrative Agent and the Secured Parties of the guaranty by such Subsidiary Guarantor under Article X of the Credit Agreement upon the execution of this Agreement by such Subsidiary Guarantor.

8.    The Borrowers confirm that the Credit Agreement is, and upon the Subsidiary Guarantors becoming Guarantors, shall continue to be, in full force and effect. The parties hereto confirm and agree that immediately upon the Subsidiary Guarantors becoming Guarantors the term “Obligations,” as used in the Credit Agreement, shall include all obligations of each Subsidiary Guarantor under the Credit Agreement and under each other Loan Document.

 

3

9.    Each Borrower and each Subsidiary Guarantor agrees that at any time and from time to time, upon the written request of the Administrative Agent, it will execute and deliver such further documents and do such further acts as the Administrative Agent may reasonably request in accordance with the terms and conditions of the Credit Agreement and the other Loan Documents in order to effect the purposes of this Agreement.

10.    This Agreement may be executed in any number of counterparts, which together shall constitute one instrument. Delivery of an executed counterpart of a signature page of this Agreement by fax transmission or other electronic mail transmission (e.g. “pdf” or “tif”) shall be effective as delivery of a manually executed counterpart of this Agreement.

11.    This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York. The terms of Sections 11.14 and 11.15 of the Credit Agreement are incorporated herein by reference, mutatis mutandis, and the parties hereto agree to such terms.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

4

IN WITNESS WHEREOF, each Borrower and each Subsidiary Guarantor has caused this Agreement to be duly executed by their respective authorized officers, and the Administrative Agent, for the benefit of the Secured Parties, has caused the same to be accepted by its authorized officer, as of the day and year first above written.

 

SUBSIDIARY GUARANTORS:              HOSPICE PREFERRED CHOICE, INC.,
    a Delaware corporation
    By:  

/s/ Scott Ginn

    Name:   Scott Ginn
    Title:   Treasurer
    HOSPICE OF EASTERN CAROLINA, INC.,
    a North Carolina corporation
    By:  

/s/ Scott Ginn

    Name:   Scott Ginn
    Title:   Treasurer
    HOMECARE PREFERRED CHOICE, INC.,
    a Delaware corporation
    By:  

/s/ Scott Ginn

    Name:   Scott Ginn
    Title:   Treasurer
    ASERACARE HOSPICE – TENNESSEE, LLC,
    a Delaware limited liability company
    By:  

/s/ Scott Ginn

    Name:   Scott Ginn
    Title:   Vice-President and Treasurer
    ASERACARE HOSPICE – SENATOBIA, LLC,
    a Delaware limited liability company
    By:  

/s/ Scott Ginn

    Name:   Scott Ginn
    Title:   Vice-President and Treasurer
    ASERACARE HOSPICE – RUSSELLVILLE, LLC,
    a Delaware limited liability company
    By:  

/s/ Scott Ginn

    Name:   Scott Ginn
    Title:   Vice-President and Treasurer

    ASERACARE HOSPICE – NEW HORIZONS, LLC,
    a Delaware limited liability company
    By:  

/s/ Scott Ginn

    Name:   Scott Ginn
    Title:   Vice-President and Treasurer
    ASERACARE HOSPICE – MONROEVILLE, LLC,
    a Delaware limited liability company
    By:  

/s/ Scott Ginn

    Name:   Scott Ginn
    Title:   Vice-President and Treasurer
    ASERACARE HOSPICE – JACKSON, LLC,
    a Delaware limited liability company
    By:  

/s/ Scott Ginn

    Name:   Scott Ginn
    Title:   Vice-President and Treasurer
    ASERACARE HOSPICE – HAMILTON, LLC,
    a Delaware limited liability company
    By:  

/s/ Scott Ginn

    Name:   Scott Ginn
             Title:   Vice-President and Treasurer
    ASERACARE HOSPICE – DEMOPOLIS, LLC,
    a Delaware limited liability company
    By:  

/s/ Scott Ginn

    Name:   Scott Ginn
    Title:   Vice-President and Treasurer
BORROWERS:     AMEDISYS, INC.,
    a Delaware corporation
    By:  

/s/ Scott Ginn

    Name:   Scott Ginn
    Title:   Chief Financial Officer and Treasurer
    AMEDISYS HOLDING, L.L.C.,
    a Louisiana limited liability company
    By:  

/s/ Scott Ginn

    Name:   Scott Ginn
    Title:   Chief Financial Officer and Treasurer

Acknowledged, accepted and agreed:
BANK OF AMERICA, N.A.,
as Administrative Agent
By:  

/s/ Joan Mok

Name:   Joan Mok
Title:   Vice President

Schedule 1

[Responsible Officers]

Intentionally Omitted.

Schedule 2

[Subsidiaries, Joint Ventures, Partnerships and Other Equity Investments]

Intentionally Omitted.

Schedule 3

[Subsidiary Information]

Intentionally Omitted.

Schedule 4

[Intellectual Property]

Intentionally Omitted.

Schedule 5

[Deposit Accounts and Securities Accounts]

Intentionally Omitted.

Schedule 6

[Real Properties]

Intentionally Omitted.

Schedule 7

[Commercial Tort Claims]

Intentionally Omitted.

Schedule 8

[Instruments, Documents and Tangible Chattel Papers]

Intentionally Omitted.

EX-101.SCH 3 amed-20200609.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 amed-20200609_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity File Number Entity File Number Entity Incorporation State Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 amed-20200609_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g944425g0613060149486.jpg GRAPHIC begin 644 g944425g0613060149486.jpg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end XML 7 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 8 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.amedisys.com//20200609/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d944425d8k.htm amed-20200609.xsd amed-20200609_lab.xml amed-20200609_pre.xml d944425dex101.htm g944425g0613060149486.jpg http://xbrl.sec.gov/dei/2019-01-31 true false ZIP 9 0001193125-20-169361-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-169361-xbrl.zip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inancial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Document and Entity Information
Jun. 09, 2020
Cover [Abstract]  
Entity Registrant Name AMEDISYS INC
Amendment Flag false
Entity Central Index Key 0000896262
Document Type 8-K
Document Period End Date Jun. 09, 2020
Entity File Number 0-24260
Entity Incorporation State Country Code DE
Entity Tax Identification Number 11-3131700
Entity Address, Address Line One 3854 American Way
Entity Address, Address Line Two Suite A
Entity Address, City or Town Baton Rouge
Entity Address, State or Province LA
Entity Address, Postal Zip Code 70816
City Area Code (225) 292-2031 or (800)
Local Phone Number 467-2662
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol AMED
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d944425d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d944425d8k.htm" ] }, "labelLink": { "local": [ "amed-20200609_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "amed-20200609_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "amed-20200609.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "amed", "nsuri": "http://www.amedisys.com/20200609", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "d944425d8k.htm", "contextRef": "duration_2020-06-09_to_2020-06-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.amedisys.com//20200609/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "d944425d8k.htm", "contextRef": "duration_2020-06-09_to_2020-06-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amedisys.com//20200609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amedisys.com//20200609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amedisys.com//20200609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amedisys.com//20200609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amedisys.com//20200609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amedisys.com//20200609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amedisys.com//20200609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amedisys.com//20200609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amedisys.com//20200609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amedisys.com//20200609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amedisys.com//20200609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amedisys.com//20200609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amedisys.com//20200609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amedisys.com//20200609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amedisys.com//20200609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amedisys.com//20200609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amedisys.com//20200609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amedisys.com//20200609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amedisys.com//20200609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amedisys.com//20200609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amedisys.com//20200609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amedisys.com//20200609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amedisys.com//20200609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 15 d944425d8k_htm.xml IDEA: XBRL DOCUMENT 0000896262 2020-06-09 2020-06-09 AMEDISYS INC false 0000896262 8-K 2020-06-09 0-24260 DE 11-3131700 3854 American Way Suite A Baton Rouge LA 70816 (225) 292-2031 or (800) 467-2662 false false false false Common Stock, par value $0.001 per share AMED NASDAQ false